Evidence map›Paper›PMID 33107395›Full record

ReviewTechnology in cancer research & treatment

A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development.

Eda G Ramirez-Valles, Alicia Rodríguez-Pulido, Marcelo Barraza-Salas, Isaac Martínez-Velis, Iván Meneses-Morales, Víctor M Ayala-García, Carlos A Alba-Fierro

Open access · goldAbstract readReview
In one paragraph

Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Eda G Ramirez-VallesFacultad de Ciencias Químicas, Universidad Juárez del Estado de Durango, Dgo, Mexico.
Alicia Rodríguez-PulidoFacultad de Ciencias Químicas, Universidad Juárez del Estado de Durango, Dgo, Mexico.
Marcelo Barraza-SalasFacultad de Ciencias Químicas, Universidad Juárez del Estado de Durango, Dgo, Mexico.
Isaac Martínez-VelisFacultad de Ciencias Químicas, Universidad Juárez del Estado de Durango, Dgo, Mexico.
Iván Meneses-MoralesFacultad de Ciencias Químicas, Universidad Juárez del Estado de Durango, Dgo, Mexico.
Víctor M Ayala-GarcíaFacultad de Ciencias Químicas, Universidad Juárez del Estado de Durango, Dgo, Mexico.
Carlos A Alba-FierroFacultad de Ciencias Químicas, Universidad Juárez del Estado de Durango, Dgo, Mexico.ORCID 0000-0001-7915-5176
Universidad Juárez del Estado de Durango · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional techniques for cancer diagnosis, such as nuclear magnetic resonance, ultrasound and tissue analysis, require sophisticated devices and highly trained personnel, which are characterized by elevated operation costs. The use of biomarkers has emerged as an alternative for cancer diagnosis, prognosis and prediction because their measurement in tissues or fluids, such as blood, urine or saliva, is characterized by shorter processing times. However, the biomarkers used currently, and the techniques used for their measurement, including ELISA, western-blot, polymerase chain reaction (PCR) or immunohistochemistry, possess low sensitivity and specificity. Therefore, the search for new proteomic, genomic or immunological biomarkers and the development of new noninvasive, easier and cheaper techniques that meet the sensitivity and specificity criteria for the diagnosis, prognosis and prediction of this disease has become a relevant topic. The purpose of this review is to provide an overview about the search for new cancer biomarkers, including the strategies that must be followed to identify them, as well as presenting the latest advances in the development of biosensors that possess a high potential for cancer diagnosis, prognosis and prediction, mainly focusing on their relevance in lung, prostate and breast cancers.

Indexed as

Biomarkers, TumorBiosensing TechniquesBreast NeoplasmsEarly Detection of CancerEpigenesis, GeneticFemaleHumansLung NeoplasmsMalePrognosisProstatic NeoplasmsProteomicsBiomarkers, Tumorbiomarkerbiosensorcancer diagnosisgenomicimmunologicpredictionprognosisproteomic

Identifiers

PMID33107395
PMCPMC7607814
OpenAlexW3094508890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.